普拉克索治疗帕金森病合并抑郁的系统评价

目的:评价普拉克索治疗帕金森病合并抑郁的疗效和安全性。方法:通过电子检索和手工检索,运用Cochrance协作网系统评价的方法对纳入所有应用普拉克索治疗帕金森病合并抑郁的随机对照试验(RCT)进行系统评价。结果:共检出5个RCT,其中3个(454例)符合纳入标准,三项研究随访时间为3-57个月。Meta分析结果显示:1)抑郁改善情况:3项研究随访结束后,应用量表进行评分,普拉克索治疗组抑郁症状改善率明显对照组,两组差异有统计学意义RR=0.63,95%CI(0.48,0.83),P<0.001];2)UPDRS评分变化:2项研究在治疗末应用UPDRS进行评分,UPDRSⅢ和Ⅱ相对于基线评分,普拉克索组均较对照组明显下降,两组之间差别有统计学意义;3)不良反应:与普拉克索组相比,对照组中因药物不良反应而终止试验研究的病例增多,两组相比有统计学差异RR=0.48,95%CI(0.34,0.69),p<0.0001]。结论:现有的临床研究证据表明,与对照组相比,普拉克索能够改善帕金森病伴发抑郁病人的抑郁症状,并减轻帕金森病的运动症状,提高病人日常生活活动能力,且安全性较高。但因研究样本局限性,尚需进行大样本长期...

Effects of pramipexole on depression in Parkinson's disease: A systematic review

Objective:To assess the effectiveness and safety of pramipexole on depression in Parkinson's disease. Methods:The method of Cochrane systematic review was used to evaluate the randomized controlled trials(RCT) of pramipexole on depression in Parkinson's disease. Results:We included 3 RCTs involving 454 patients. The duration of follow-up was three to fifty-seventh month. The results of meta-analyses indicated the depression was significantly improved after pramipexole treatment compared to the control group...